<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24144784</identifier>
<setSpec>1578-1852</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Palazuelos, Marta</dc:author>
<dc:author>Ledesma, Francisco</dc:author>
<dc:author>Viciana, Pompeyo</dc:author>
<dc:author>Ocampo, Antonio</dc:author>
<dc:author>Hevia, Henar</dc:author>
<dc:description xml:lang="en">INTRODUCTION The purpose of Perfil-es study was to identify the proportion of patients starting ARV treatment based on NNRTIs or PI/r, and to identify the variables involved in the therapeutic decision-making in standard clinical practice. METHODS An observational retrospective study performed in 65 Spanish hospitals. RESULTS Was a total of 1,687 starts: 53% with NNRTI-based regimen and 42% with PI/r, and of the 642 patients analyzed, 72% had a CD4 count&lt;350 cells/μl. CONCLUSION The initiation of ARV treatment is still late in Spain. NNRTIs are the more frequent choice, although PI/r plays an important role.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Inhibidor de la transcriptasa inversa no análogo de nucleósidos</dc:subject>
<dc:subject>Non-nucleoside reverse transcriptase inhibitors</dc:subject>
<dc:subject>Protease inhibitors</dc:subject>
<dc:subject>Tratamiento antirretroviral</dc:subject>
<dc:subject>Human immunodeficiency virus</dc:subject>
<dc:subject>Virus de la inmunodeficiencia humana</dc:subject>
<dc:subject>Naive</dc:subject>
<dc:subject>Inhibidor de la proteasa potenciado con ritonavir</dc:subject>
<dc:subject>Antiretroviral treatment</dc:subject>
<dc:date>2014 Feb </dc:date>
<dc:title xml:lang="es">Tratamiento antirretroviral de inicio en pacientes infectados por el virus de la inmunodeficiencia humana en España: decisiones con relación a características inmunovirológicas específicas (estudio PERFIL-es).</dc:title>
<dc:title xml:lang="en">[Initial antiretroviral treatment in human immunodeficiency virus-infected patients in Spain: Decisions made in relation to particular immunovirological characteristics (PERFIL-es study)].</dc:title>
<dc:publisher>Enfermedades infecciosas y microbiologia clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
